Int J Med Sci 2021; 18(3):835-845. doi:10.7150/ijms.50122 This issue Cite

Review

Ocoxin as a complement to first line treatments in cancer

Aitor Benedicto1, Eduardo Sanz2, Joana Márquez1✉

1. Department of Cellular Biology and Histology, School of Medicine and Nursing, University of the Basque Country, 48940, Leioa, Bizkaia, Spain.
2. Catalysis S.L., Toledo, Spain.

Citation:
Benedicto A, Sanz E, Márquez J. Ocoxin as a complement to first line treatments in cancer. Int J Med Sci 2021; 18(3):835-845. doi:10.7150/ijms.50122. https://www.medsci.org/v18p0835.htm
Other styles

File import instruction

Abstract

Chemotherapy and radiotherapy are the most frequent treatment for patients suffering from malignant progression of cancer. Even though new treatments are now being implemented, administration of these chemotherapeutic agents remains as the first line option in many tumor types. However, the secondary effects of these compounds represent one of the main reasons cancer patients lose life quality during disease progression. Recent data suggests that Ocoxin, a plant extract and natural compound based nutritional complement rich in antioxidants and anti-inflammatory mediators exerts a positive effect in patients receiving chemotherapy and radiotherapy. This mixture attenuates the chemotherapy and radiotherapy-related side effects such as radiation-induced skin burns and mucositis, chemotherapy-related diarrhea, hepatic toxicity and blood-infection. Moreover, it has been proven to be effective as anticancer agent in different tumor models both in vitro and in vivo, potentiating the cytotoxic effect of several chemotherapy compounds such as Lapatinib, Gemcitabine, Paclitaxel, Sorafenib and Irinotecan. The aim of this review is to put some light on the potential of this nutritional mixture as an anticancer agent and complement for the standard chemotherapy routine.

Keywords: Ocoxin, natural product, antioxidant, anti-inflammatory, cancer, chemorresistance, coadjuvant


Citation styles

APA
Benedicto, A., Sanz, E., Márquez, J. (2021). Ocoxin as a complement to first line treatments in cancer. International Journal of Medical Sciences, 18(3), 835-845. https://doi.org/10.7150/ijms.50122.

ACS
Benedicto, A.; Sanz, E.; Márquez, J. Ocoxin as a complement to first line treatments in cancer. Int. J. Med. Sci. 2021, 18 (3), 835-845. DOI: 10.7150/ijms.50122.

NLM
Benedicto A, Sanz E, Márquez J. Ocoxin as a complement to first line treatments in cancer. Int J Med Sci 2021; 18(3):835-845. doi:10.7150/ijms.50122. https://www.medsci.org/v18p0835.htm

CSE
Benedicto A, Sanz E, Márquez J. 2021. Ocoxin as a complement to first line treatments in cancer. Int J Med Sci. 18(3):835-845.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.